Latest Arexera Therapeutics News & Updates

See the latest news and media coverage for Arexera. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Arexera Therapeutics (Arexera)

Biotechnology company developing genetic medicines for neurological diseases

arexeratx.com
Headquarters
Boston, United States
Company type
Private company
Number of employees
51–200

Last updated

Latest news about Arexera Therapeutics (Arexera)

In short: Arexera secured China IND approval for ATL-101, advancing its Huntington’s disease therapy toward Phase 1.

Company announcements

Arexera

Arexera Therapeutics unveils new corporate identity and advances HD franchise

Formerly Atalanta Therapeutics, the company reports preclinical ATL-101 data showing durable HTT suppression and plans a Phase 1 study in Huntington's patients by end of 2026, alongside MSH3 programs.

Unlock all announcements with a

Media coverage

BioWorld

Atalanta, now Arexera Therapeutics, reports pipeline update

Arexera Therapeutics Inc., formerly Atalanta Therapeutics Inc., has unveiled its new name as it builds a Huntington's disease franchise designed to address complementary drivers of...

Unlock all articles with a

Never miss news about Arexera

Track Arexera and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.